InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Browse the detailed record of transactions filed by Melnick David A., Directeur Médical. Director active across 1 company, notably Spero Therapeutics, Inc.. Aggregated, 2 disclosures have been recorded. History available since 26 August 2021. The latest transaction was filed on 1 February 2022 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Melnick David A.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
38,014 shares0Common StockSEC:0000899243-22-004594:0
24,067 shares0Common StockSEC:0000899243-21-034503:0
2 of 2 declarations
About Melnick David A.
David A. Melnick serves as Chief Medical Officer at Spero Therapeutics, Inc. In this role, he is responsible for leading the company's medical initiatives and clinical research. With a strong background in the pharmaceutical sector, David contributes to innovation and treatment improvement. His leadership is essential in ensuring that Spero Therapeutics adheres to ethical and scientific standards.
